How TrueCurrent Got Outside the Tech Cluster

On August 19, Moderna and Merck reported interim Phase 3 results for a personalized cancer therapy. MRNA closed the day up roughly 491% on the year.

Onchain traders looking for a market to trade it in mostly came up empty. Several venues added MRNA that afternoon, reacting to the news. TrueCurrent had listed it over a month ago (July 9th), alongside eight other healthcare and biotech names, none of which had done anything in particular at the time.

Open any onchain venue offering stock perpetuals and the catalog is familiar. Apple, Tesla, Nvidia, Microsoft. A few semiconductors, AI, and compute.

Pyth Pro prices 1,024 US equities. Onchain, traders see a fraction of that, concentrated almost entirely in one sector. The usual explanation is demand. Traders want technology stocks, so venues list technology stocks. That explanation is hard to test when venues rarely offer traders anything else to want.

Two Constraints, Not One

A new market needs two things: a price and liquidity. Onchain equity venues have been short on both, and the shortages reinforce each other.

Start with the price. A stock perpetual needs a reference that runs continuously and tracks the underlying market, available under terms that permit redistribution into a trading venue. Traditional market-data licensing was designed around terminals and internal desks. Publishing a price into a public trading venue is a different commercial arrangement, often negotiated venue by venue and symbol by symbol.

The question before a listing is therefore not only whether traders might want the market. It is whether the price for that ticker can be sourced, delivered and redistributed at a cost that justifies the listing.

Then liquidity. On an orderbook venue, a listing is can be of limited use until a book forms around it. Thin books produce poor fills, poor fills can push traders elsewhere, and the market may struggle to gain traction. Every additional listing divides liquidity-provider attention, so orderbook venues have a structural reason to keep their catalogs concentrated in names expected to trade.

Market-data networks loosen the first constraint. They do not solve the second on their own. Listing and liquidity mechanics still shape the catalog, which helps explain why onchain equity trading has stayed clustered around a short list of large-cap technology names.

What TrueCurrent Changed

TrueCurrent is a non-custodial perpetuals exchange. It uses an RFQ model rather than a traditional orderbook. A trader sets the parameters of a trade and a worst acceptable price, TrueCurrent collects quotes from professional liquidity providers, and execution routes to the best available quote.

For listings, the important difference is that there is no resting orderbook to bootstrap. A new market needs providers willing to quote it and a reliable price feed to quote against. It does not need a resting orderbook to become usable.

That moves the marginal listing constraint onto the cost and availability of reliable pricing.

The listing decision becomes a product question: which markets should the venue make available, when the price data already exists?

The Coverage Underneath

Pyth Pro currently catalogs 1,024 stable US spot-equity feeds across its live production catalog. All 1,024 include regular-session coverage. 434 add at least one pre-market, post-market or overnight session, and 222 include all four sessions for full 24/5 coverage.

Pyth's market-data network draws direct contributions from more than 125 publishers. The resulting universe reaches well beyond technology into healthcare, defense, industrials, financials, energy and consumer markets.

The integration surface is one API across a broad, machine-readable feed catalog. A venue uses the same integration pattern as its market universe grows, evaluating listings against its own users, liquidity providers and risk controls.

The data question and the listing question come apart.

What That Produced

Today, TrueCurrent lists 112 equity perpetual markets using Pyth Pro price feeds, alongside FX, precious-metals and crude-market feeds.

Technology is the largest category at 28 markets, and it accounts for a quarter of the list. The other three quarters sit outside the cluster that dominates onchain equity trading.

Healthcare and biotech include Amgen, Gilead, Intuitive Surgical, Lilly, Moderna, Novo Nordisk, Pfizer and Regeneron. Defense and aerospace include Boeing, General Dynamics, Lockheed Martin, Northrop Grumman, Rocket Lab and RTX. Energy, utilities and materials include Enphase, First Solar, NextEra, Oklo, Rio Tinto and Vistra. Financials include BlackRock, Blackstone, CME Group, Goldman Sachs, JPMorgan, KKR, Morgan Stanley and Schwab.

"Most venues list what already trades, which is why onchain equities look like the same dozen tech names everywhere you go. We built it the other way around. Our RFQ model doesn't need a deep resting orderbook, and Pyth Pro gives us reliable prices across the full equity universe, so we can list a market because the data exists and traders might want it, not because it already has volume. That's why Moderna, along with a lot of healthcare, defense, and energy names, was live on TrueCurrent before the catalyst arrived, not the afternoon after.” — TrueCurrent spokesperson.

The Moderna Case

The catalysts behind that move ran through most of 2026.

Two catalysts drove most of it. The FDA approved the company's mRNA flu vaccine earlier in the year. Then on August 19, interim Phase 3 results for a personalized cancer therapy developed with Merck met their primary endpoint, and the stock moved hard enough that several perp venues added the market the same day.

By the August 19 close, MRNA was up approximately 491% year to date, rising from $29.50 at the December 31, 2025 close to $174.38, based on Pyth Pro daily history for Equity.US.MRNA/USD.

The point is not that TrueCurrent caught one stock. Reactive listing works when a venue happens to be watching. Coverage works regardless, and a catalog assembled around what might trade behaves differently from one assembled around what already trades.

Why This Matters

Onchain equity trading has been running one trade in a dozen interfaces. A cluster of correlated large-cap technology names, moving around the same market thesis, available everywhere.

That shape reflects data access, listing economics and the mechanics of bootstrapping liquidity as much as it reflects what traders want. TrueCurrent changed one side of it with an RFQ model that does not depend on a deep resting orderbook, which freed the venue to evaluate markets against available price coverage rather than expected day-one volume.

Pyth Pro catalogs 1,024 stable US spot-equity feeds. TrueCurrent makes 112 of them tradeable onchain, across eight sectors. Find the full catalog on the Pyth Terminal.